Launch offer: full deHype evidence reports are £4.99 for a limited time.

Check a headline

Evidence type

Animal studies

Animal studies can provide valuable insights into biological processes and potential effects of interventions. However, results from animal experiments may not translate to humans. This page explains why animal research can inform but not confirm health claims about people.

Animal studies play a significant role in early stages of biomedical research. Scientists use animal models to test hypotheses about how diseases work and how potential treatments may affect biological systems. These studies allow researchers to explore effects that might not be ethical or feasible to study in humans at first.

What do animal studies show?

  • Mechanism exploration: Animal experiments can reveal underlying biological mechanisms and how substances interact with living tissues.
  • Safety signals: They help spot possible safety problems before human trials.
  • Hypothesis generation: Results in animals often lay the groundwork for further research or human trials.

What animal studies cannot prove

  • Human effectiveness: Findings in animals do not guarantee the same outcomes in people due to differences in biology.
  • Clinical benefits: Success in animals does not confirm a treatment will work, and be safe, in humans.
  • Translation problems: Many treatments that work in animals have failed when tested in humans.

deHype interpretation

Animal research is important for identifying promising scientific directions and potential safety risks. However, it is a weak form of evidence for health claims relevant to people unless supported by human trials. Health decisions should not be based solely on animal study results.

Frequently Asked Questions

  • Q: Why do so many animal studies make the news?
    A: Early findings can be interesting and generate media coverage, but these results rarely lead directly to human treatments.
  • Q: Can I trust claims based only on animal research?
    A: Caution is needed. Only results from well-conducted human research should form the basis for health decisions or treatment claims.
  • Q: Are there alternatives to animal studies?
    A: Where possible, researchers use cell studies, computer models, or human tissues, but entire living systems are sometimes needed to understand complex effects.
  • Q: Why do so many animal studies make the news?
    A: Early findings can be interesting and generate media coverage, but these results rarely lead directly to human treatments.
  • Q: Can I trust claims based only on animal research?
    A: Caution is needed. Only results from well-conducted human research should form the basis for health decisions or treatment claims.
  • Q: Are there alternatives to animal studies?
    A: Where possible, researchers use cell studies, computer models, or human tissues, but entire living systems are sometimes needed to understand complex effects.

Reports

Related deHype reports

Specific public claims connected to this topic.

Report · Grade C Evidence check: Your nose could detect Alzheimer’s years before symptoms begin The article reports that loss of smell may be an early indicator of Alzheimer's, based on research showing the brain's immune cells destroy connections between the olfactory bulb and locus coeruleus in both animal models and human tissue. The immune activity is thought to begin before visible cognitive decline, which could permit earlier identification and interventions against Alzheimer's. However, while there is supporting animal evidence and some human tissue and imageing data, prospective clinical validation for smell loss as a biomarker is lacking. Report · Grade D Evidence check: Science & Medicine: A pill that slows aging? San Antonio researchers are putting it to the test The article describes a clinical trial at UT Health San Antonio testing whether rapamycin, which extended both lifespan and healthspan in mice, can restore 'youthful' biological markers in older adults by modulating the mTOR pathway. While animal studies have shown rapamycin to reverse markers of arterial hardening and improve healthspan, no published human results on actual ageing-related health outcomes are reported. The human study underway measures immune and metabolic markers in older adults after rapamycin or everolimus treatment but has not reported clinical results. Report · Grade D Evidence check: Scientists Discover Brain Pathway That May Slow Parkinson’s Disease – but Only in Women The article reports on a preclinical study in the Journal of Neuroscience that used gene editing to increase the number of nicotine-responsive receptors in dopamine-producing neurons of mice, resulting in neuroprotection under parkinsonian conditions, but only in female models. The authors propose this pathway as a potential strategy to slow disease progression. There is no evidence of testing in humans, and the findings are limited to animal models. Report · Grade D Evidence check: Scientists found a hidden Alzheimer’s trigger and shut it down The ScienceDaily article reports that researchers from Indiana University School of Medicine identified a potential Alzheimer’s treatment target: the enzyme IDOL. Their laboratory animal studies found that deleting IDOL from neurons led to a reduction in amyloid plaques and increased markers of brain resilience and communication. However, the research is fully preclinical; it has not yet been tested in humans, and clinical benefits or safety are unknown. Report · Grade D Evidence check: A hidden map in your nose could explain how smell works This ScienceDaily article reports on new research in mice that mapped millions of olfactory neurons and found that smell receptors are arranged in neat, overlapping stripes depending on receptor type. This organization mirrors how smell is mapped in the brain. The research, published in Cell, reveals a coordinated sensory system and suggests that understanding this mapping could guide future treatments for loss of smell, such as stem cell therapies or brain-computer interfaces. However, the finding is based on mouse, not human, studies, and no direct therapeutic demonstrations are provided. Report · Grade C Evidence check: Why some brain cells are particularly vulnerable to multiple sclerosis The article describes new research identifying that a specific set of brain cells (CUX2 neurons) are especially susceptible to dying in the context of progressive multiple sclerosis because DNA damage caused by inflammation exceeds their ability to repair themselves. The research involved both human postmortem tissue from MS patients and mouse models where DNA repair proteins (notably ATF4) were experimentally disabled, aggravating neuron loss. The findings suggest that, beyond the traditionally-recognized loss of myelin, intrinsic neuronal vulnerability and impaired DNA repair are critical in the neurodegenerative progression of MS. This opens the possibility of future therapies aimed at protecting these neurons but has not established any immediate treatment or clinical recommendations. Report · Grade D Evidence check: New psychedelic-like drugs could treat depression without making you trip The article reports that UC Davis scientists discovered and synthesized a new class of compounds from amino acids using UV light, which activate the serotonin 5-HT2A receptor—the main target of psychedelic drugs—but did not induce the hallmark head-twitch response (a proxy for hallucinations) in mice. This leads researchers to speculate that these agents could offer the brain-healing or therapeutic potential of psychedelics without the perceptual side effects, potentially paving the way for future depression, PTSD, and addiction drugs. All findings thus far are limited to laboratory and animal studies; no human or clinical data are reported.

Helpful evidence guides

Animal studies vs human trials Animal studies can reveal biological mechanisms and offer important early clues, but results from animal research do not guarantee that those findings will translate into proven benefits for humans. Clinical trials in humans are needed to determine safety and effectiveness before an intervention can be recommended for people. How deHype grades claims Learn how deHype evaluates health and science claims with a transparent grading system based on strength, relevance, and quality of evidence.

Related evidence pages

Cell studies How in-vitro and cell-line findings should be interpreted in health headlines. Cell studies investigate the effects of substances or genetic changes in isolated cells outside the human body. While these studies can show how something may work at a basic biological level, their results do not directly apply to human health without further research. Guidelines Guidelines translate research evidence into recommendations for clinical practice, but their strength can vary depending on the available evidence, expert interpretation, and other practical factors. Observational studies Observational studies look for associations in real-world populations but do not automatically prove that one factor causes another. Other explanations—including confounding and reverse causation—are important to consider when interpreting their results. Randomised trials Randomised trials are a key method for testing the effects of medical and health interventions. By randomly assigning participants, these studies aim to balance differences between groups and reduce bias, making their findings more reliable. However, they are not free from limitations, and careful interpretation is still needed. Systematic reviews Systematic reviews summarise multiple studies using transparent, pre-specified methods. Their strength as evidence depends not only on their process but also on the quality and relevance of the included studies.
Seen a headline in this area? Paste the link and get a deHype evidence check.
Check a headline